Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    polle1
    wrote on sidst redigeret af
    #350

    Godmorgen og god dag 🙂

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #351

      E L with the new DKd arm in the phase II kombination study with sc dara it for sure now must be only filing for mono sc dosing this year - and then probably first combination filing next year and if we are unlucky approval in early 2021 for sc dosing in combination

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #352

        Link Preview Image
        Medicin til 13 mio kr per behandling rammer markedet i USA

        En genterapi til muskelsvind hos spædbørn tegner til at tage rekorden for den hidtil dyreste behandling på det amerikanske marked med i pris i omegnen af to mio. dollar.

        favicon

        (medwatch.dk)

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #353

          Måske også et spørgsmål til Jan omkring prispolitikken i USA

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #354

            Just a moment...

            favicon

            (www.firstwordpharma.com)

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #355

              Lidt om BCMAs manglende duration:

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #356

                A new study appearing in Leukemia Research from researchers at the Institute for Myeloma & Bone Cancer Research seeking to better understand the phenomenon evaluated 379 samples from relapsed/refractory MM patients and found elevated levels soluble BCMA that were associated with reduced binding by an inhibitory antibody. The group thus suggested that free-floating protein act as a “decoys” that may contribute to diminished efficacy of anti-BCMA therapies.

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #357

                  One possible solution to the issue of circulating BCMA that has been proposed is to combine a direct antagonist, be it a CAR-T construct or antibody-based therapy, with an inhibitor of gamma secretase, an enzyme that cleaves transmembrane proteins and is believes to lead to increased levels of soluble BCMA.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #358

                    Novartis is one of the companies that has moved aggressively in this area, partnering to test Ayala Pharmaceuticals’ AL102 in combination with the Swiss pharma’s CAR-T therapy. Juno Therapeutics (acquired by Celgene last year), also licensed a gamma secretase inhibitor from Eli Lilly in late 2017, though Amin noted that nothing has been heard about the programme in the years since.

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #359

                      Og nu vi talte om dara i
                      Kina så seneste update fra MorphoSys: - MOR202: Pivotal phase 2 study in third line and phase 3 study in second line multiple myeloma started by partner I-Mab in Taiwan

                      1 Reply Last reply
                      0
                      • StockBullS Offline
                        StockBullS Offline
                        StockBull
                        wrote on sidst redigeret af
                        #360

                        Morn 🙂 det bliver en spændende dag selv om jeg mest forventer en non event og fortsat markeds tillid til Genmab

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #361

                          Jeg har tillid til Jan og Co. har styr på sagerne og det har markedet tilsyneladende også eftersom Genmab er højest værdisatte aktie i C25

                          1 Reply Last reply
                          0
                          • concilladoC Offline
                            concilladoC Offline
                            concillado
                            wrote on sidst redigeret af
                            #362

                            Har GEN endelig slået APM af grenen? 😉

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #363

                              @sukkeralf: Har du nogen ide om, hvad det betyder for bispecifikke f.eks. cd3xBCMA? (JNJ-64007957)

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #364

                                Nej ikke umiddelbart - gætter på samme problem omend der måske er en fordel ved at man har mere styr på dosering af lægemidlet ved gentagne infusioner.

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #365

                                  tak

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    jkj
                                    wrote on sidst redigeret af
                                    #366

                                    sydbank,s forventninger

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      jkj
                                      wrote on sidst redigeret af
                                      #367

                                      https://data.sydbank.dk/api/investment/sydbank/publications/file/110780

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        jkj
                                        wrote on sidst redigeret af
                                        #368

                                        Det bliver ikke de kønneste tal at kigge på, så vi må håbe at de noget andet med i posen til os.

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          bibob
                                          wrote on sidst redigeret af
                                          #369

                                          Ok analyse fra Sydbank. De er sjældent negative på Genmab. 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger